Abstract 928P
Background
The prediction of early response in locally advanced nasopharyngeal carcinoma (LA-NPC) after concurrent chemoradiotherapy (CCRT) is indeed important for determining the need for timely consolidation therapy. Radiomics has helped medical imaging expand from diagnostic to a personalized clinical decision aid, while most traditional radiomics primarily focus on mono-sequence. Recently, multi-MR sequences model has shown better outcomes in the management of many cancers. However, the validation of a radiomic analysis of multi-MR sequences based on machine learning for this purpose is currently lacking for patients with LA-NPC after CCRT.
Methods
This study comprised 104 patients with LA-NPC, of which 70% were allocated for training and the remaining 30% were used for internal validation. We extracted radiomics features corresponding to each mono-sequences (T1, T1C, T2, DWI, and ADC), and then applied LASSO for feature selection and constructed the risk model using machine learning algorithms including SVM, Random Forest, ExtraTrees, XGBoost and LightGBM. Performance comparisons were made between mono-sequences and then feature fusion was performed to construct a multi-MR sequences model. Clinical features were numerically mapped and analyzed using machine learning algorithms similar to those in the Radiomics Model. Finally, we created a combined model that integrated the radiomics and clinical models to enhance clinical relevance, whose diagnostic effectiveness was evaluated using receiver operator characteristic (ROC) curves in the test cohort.
Results
In the training cohort, while the Clinic model achieved an Area Under the Curve (AUC) of 0.892 and the Fusion model reached 0.972, the Combined model excelled with an AUC of 0.990. Similarly, in the test cohort, the Combined model outperformed both the Clinic (AUC: 0.852) and Fusion models (AUC: 0.886), achieving an AUC of 0.900.
Conclusions
As a result, a combined model, which merges clinical and multi-MR sequences radiomics model, showed good performance for predicting early response of LA-NPC after CCRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program and Jiangsu Province People's Hospital Clinical Capability Enhancement Project.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1036P - Large-scale cellular profiling of 1283 cancer patients reveals a NK cell-mediated immunosuppressive tumor microenvironment in immunotherapy resistance
Presenter: Yumo Xie
Session: Poster session 03
1037P - Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484
Presenter: Hakimeh Ebrahimi-Nik
Session: Poster session 03
Resources:
Abstract
1038P - Interactions of immune checkpoint blockade and regulatory T cells
Presenter: Dylan Muldoon
Session: Poster session 03
1039P - Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy
Presenter: Eduard Teixidor Vilà
Session: Poster session 03
1040P - Chemotherapy remodels the tumor immune microenvironment to increase the pCR rate of anti-PD-1 neoadjuvant therapy in MSS/pMMR locally advanced colon cancer: A prospective clinical trial and translational study
Presenter: Changjing Cai
Session: Poster session 03
Resources:
Abstract
1041P - ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1
Presenter: Pierre MARSCHALL
Session: Poster session 03
1042P - Rapid, single-step monitoring of circulating monoclonal antibodies using an aptamer-based electrochemical sensing platform
Presenter: Raffaella Ergasti
Session: Poster session 03
1043P - Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations
Presenter: Kirsty Crame
Session: Poster session 03
1044P - UniTope & TraCR: Universal tagging and tracking system for TCR-T cells integrated directly in the TCR constant region
Presenter: Kirsty Crame
Session: Poster session 03
1045P - The association of human leukocyte antigen variants in immune-related toxicity and efficacy in Chinese lung cancer patients treated with immune checkpoint inhibitors
Presenter: Yongchang Zhang
Session: Poster session 03